Hydrus® microstent


Thiago Moulin

Arsham Sheybani

Buy this article


The Hydrus® Microstent (Ivantis, Inc, Irvine, CA, USA) is an 8 mm crescent-shaped nitinol intracanalicular implant. This microinvasive glaucoma surgery (MIGS) device serves both as a stent and as a Schlemm’s canal (SC) scaffold, allowing direct passage of aqueous through its lumen and also dilating the canal. The implant facilitates aqueous outflow through natural pathways, does not require filtration blebs, and is inserted ab interno.
In August of 2018, the FDA approved the Hydrus to be implanted with concomitant cataract surgery (CS) upon publication of the pivotal HORIZON trial.1 Worldwide, however, the device had already been implanted over 3,300 times, being in use in the European Union as early as 2011,2 and since then also being marketed in Canada, Australia, New Zealand, Costa Rica, and Colombia.3 In addition to supporting the approval, the HORIZON study also boasted excellent results, with 77% of patients showing a ≥ 20% intraocular pressure (IOP) decrease after 2 years of the procedure, or 20% more patients than those submitted to CS alone.

New Concepts in Glaucoma Surgery Series: Volume 1, pp. 107-118 #8
Edited by: John R. Samples and Iqbal Ike K. Ahmed
© Kugler Publications, Amsterdam, The Netherlands

Buy this article

Kugler Publications

Kugler Publications

Postal address:
P.O. Box 20538
1001 NM Amsterdam
The Netherlands
Tel: +31 20 68 45 700

© 2022 Kugler Publications.